Machine Learning In Pharmaceutical Industry Market Size 2025-2029
The machine learning in pharmaceutical industry market size is forecast to increase by USD 10.2 billion, at a CAGR of 37.1% between 2024 and 2029.
The global machine learning in pharmaceutical industry market is shaped by the increasing volume and complexity of data generated throughout the drug development lifecycle. This influx of genomic, proteomic, and clinical data necessitates advanced analytical tools to extract meaningful insights. Machine learning algorithms, including those used in drug discovery technology, are essential for identifying patterns in these large datasets, thereby accelerating target identification and predictive toxicology modeling. The rise of generative AI for de novo drug design represents a significant trend, allowing for the creation of novel molecular structures with desired therapeutic properties from scratch. This approach expands the explorable chemical space and quickens the lead optimization phase, contributing to advancements in computer-aided drug discovery.However, the market's potential is constrained by the pervasive issue of data silos and a lack of interoperability across different systems and organizations. This fragmentation impedes the training of robust machine learning models that require comprehensive, integrated datasets. Overcoming these data-sharing hurdles is critical for leveraging the full capabilities of AI in pharmaceutical research. Despite this, the integration of AI is crucial for optimizing various stages of the value chain, from R&D to pharmaceutical continuous manufacturing market, underscoring its indispensable role in the future of medicine.
What will be the Size of the Machine Learning In Pharmaceutical Industry Market during the forecast period?
Explore in-depth regional segment analysis with market size data - historical 2019 - 2023 and forecasts 2025-2029 - in the full report.
Request Free Sample
The global machine learning in pharmaceutical industry market is characterized by continuous advancements in computational methods that are reshaping drug development paradigms. The integration of AI in predictive toxicology and other preclinical phases is becoming standard practice, enabling more accurate forecasts of compound safety and efficacy. Advanced algorithms for real-world evidence analysis are providing deeper insights into treatment outcomes and patient behaviors outside of controlled clinical settings. This evolution is supported by progress in computer-aided drug discovery, which leverages sophisticated models to identify and optimize promising therapeutic candidates.Furthermore, the application of patient stratification algorithms is refining clinical trial designs, leading to more targeted and efficient studies. The development of digital biomarker integration with wearable technology is creating new endpoints for assessing treatment response in real time. These dynamic shifts highlight a move toward more data-centric and personalized approaches across the pharmaceutical value chain, from initial research to post-market surveillance. The ongoing refinement of these technologies ensures their expanding role in addressing complex medical challenges.
How is this Machine Learning In Pharmaceutical Industry Industry segmented?
The machine learning in pharmaceutical industry industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.
- Application
- Drug discovery and design
- Clinical trial optimization
- Disease diagnosis and biomarker identification
- Manufacturing and quality control
- Others
- Technology
- Supervised learning
- Deep learning
- Unsupervised learning
- Reinforcement learning
- Others
- Deployment
- Cloud-based
- Hybrid
- On premises
- Geography
- North America
- APAC
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Europe
- Germany
- UK
- France
- Italy
- The Netherlands
- Spain
- South America
- Middle East and Africa
- Rest of World (ROW)
By Application Insights
The drug discovery and design segment is estimated to witness significant growth during the forecast period.
The drug discovery and design segment is a important area within the global machine learning in pharmaceutical industry market. It involves the use of machine learning algorithms for high-throughput screening, target identification, and lead optimization. These technologies analyze complex biological and chemical data to predict molecular interactions and ADMET profiles, significantly reducing the time and cost of early-stage research. This data-driven approach allows for the prioritization of promising drug candidates and accelerates their progression into preclinical development, with some regional markets contributing as much as 5.35% to the global opportunity.
Furthermore, machine learning facilitates de novo drug design, where generative models create entirely new molecular structures optimized for specific therapeutic functions. This capability expands the chemical space beyond what traditional methods can achieve, enabling the development of first-in-class therapies. The integration of predictive models for tasks like chemical library screening and computational chemistry is enhancing the efficiency of the drug discovery process. This focus on AI-driven innovation is critical for addressing unmet medical needs and improving the overall productivity of pharmaceutical R&D pipelines.
Request Free Sample
The Drug discovery and design segment was valued at USD 235.30 million in 2019 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 41.3% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Request Free Sample
North America is the dominant region in the global machine learning in pharmaceutical industry market, driven by its robust R&D infrastructure and significant investment in biotechnology. The region, particularly the United States, hosts a high concentration of leading pharmaceutical companies, innovative startups, and prominent academic institutions actively engaged in machine learning initiatives. A proactive regulatory environment and substantial venture capital funding create a dynamic ecosystem for technological advancement. This leadership is reflected in its significant market share, with other regions like the Middle East and Africa contributing a smaller but growing share of around 4.79% to the global landscape.
The prevalence of large, integrated healthcare systems in North America generates vast amounts of real-world data, which is crucial for training and validating machine learning models in areas like personalized medicine and disease diagnosis. The region's advanced computing infrastructure and strong intellectual property protection laws further encourage innovation and investment in proprietary machine learning platforms. This combination of factors ensures North America's continued leadership in the global machine learning in pharmaceutical industry market, with a strong focus on pharmacovigilance automation and other advanced applications.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The global machine learning in pharmaceutical industry market is experiencing unprecedented growth, driven by the adoption of sophisticated technologies across the R&D spectrum. Companies are increasingly leveraging AI for target identification drug discovery and utilizing AI platforms for small molecule design to accelerate early-stage development. The application of generative AI for protein based therapeutics is revolutionizing treatment creation, complemented by reinforcement learning for molecule design and AI driven protein engineering. Furthermore, the integration of data science platforms for neuroscience is enhancing research in complex areas, particularly through machine learning for alzheimer drug discovery. The use of deep learning for genomic data analysis is becoming standard, enabling a more profound understanding of disease mechanisms.This expansion extends to clinical development and specialized therapeutic areas, where AI for clinical trial data analysis is critical. The deployment of machine learning models for clinical trial outcomes and the application of predictive analytics for patient stratification are personalizing medicine. Significant traction is seen in specific domains, including machine learning for rheumatoid arthritis and predictive modeling for metabolic disease therapies. The oncology sector benefits from predictive modeling for oncology pipelines and machine learning for immuno oncology combinations. Similarly, specialized machine learning algorithms for gastroenterology and predictive analytics for plasma derived therapies are gaining prominence. The entire ecosystem is supported by advanced AI driven platforms for analyzing biomedical data, with focused applications in machine learning for biologics development and AI in immunology drug design pushing the boundaries of innovation.
What are the key market drivers leading to the rise in the adoption of Machine Learning In Pharmaceutical Industry Industry?
- The primary driver for the global machine learning in the pharmaceutical industry market is the increasing volume and complexity of data generated across the entire pharmaceutical value chain.
The increasing volume and complexity of data across the pharmaceutical value chain are a primary driver for the global machine learning in pharmaceutical industry market. Modern drug development processes generate vast amounts of diverse data, including genomic sequences, clinical trial results, and real-world evidence, which traditional analytical methods cannot efficiently process. Machine learning algorithms are designed to identify subtle patterns and correlations within these complex datasets, which is crucial for tasks like novel drug target identification, patient stratification, and predictive toxicology modeling. The ability of machine learning to convert intricate data into actionable intelligence is accelerating drug discovery timelines and improving clinical development success rates, with a significant portion, 41.3%, of the market's incremental growth attributed to regions with strong data infrastructure.The relentless pursuit of enhanced efficiency and reduced costs throughout the drug lifecycle is another significant factor driving the global machine learning in pharmaceutical industry market. Pharmaceutical R&D is notoriously expensive and time-consuming, with high failure rates in clinical trials. Machine learning provides powerful solutions to these challenges by optimizing various stages of drug development. In drug discovery, it accelerates target identification and validation, while in clinical trials, it improves patient recruitment and trial design, leading to faster, more cost-effective studies. This capability to automate tasks and provide predictive insights directly contributes to significant cost savings and operational efficiencies. The imperative to innovate more economically in a competitive global market continues to fuel the adoption of machine learning solutions, such as pharmacovigilance automation, across the pharmaceutical sector.
What are the market trends shaping the Machine Learning In Pharmaceutical Industry Industry?
- A prominent trend shaping the global machine learning in pharmaceutical industry market is the rapid rise of generative AI for de novo drug design.
A prominent trend influencing the global machine learning in pharmaceutical industry market is the rapid emergence of generative AI for de novo drug design. This technology is transforming traditional drug discovery paradigms by creating entirely novel molecular structures with desired therapeutic properties. Advanced machine learning architectures like generative adversarial networks learn the complex relationships between chemical structures and biological activities, generating new compounds optimized for specific targets. This capability significantly expands the chemical space available for exploration, accelerating hit identification and lead optimization. This approach, integral to modern drug discovery informatics market, is particularly impactful for addressing unmet medical needs. The market's expansion in regions that contribute 27.07% to its growth is partly due to the adoption of such advanced technologies.The increasing adoption of federated learning for data privacy and collaborative research is another crucial trend. Amid stringent data protection regulations and concerns over patient data privacy, sharing sensitive information for machine learning model training poses significant challenges. Federated learning addresses this by enabling models to be trained on decentralized datasets without moving the raw data. This approach fosters multi-institutional collaboration, which is vital for developing robust models for disease diagnosis, biomarker identification, and personalized medicine while maintaining strict data confidentiality. The use of federated learning is becoming a key component of artificial intelligence in biotechnology, mitigating risks associated with data breaches and ensuring regulatory compliance, solidifying its position as a transformative trend.
What challenges does the Machine Learning In Pharmaceutical Industry Industry face during its growth?
- A significant challenge impeding the full potential of the global machine learning in pharmaceutical industry market is the pervasive issue of data silos and a lack of interoperability.
A primary challenge for the global machine learning in pharmaceutical industry market is the prevalence of data silos and a lack of interoperability. The pharmaceutical sector generates vast amounts of data from diverse sources like R&D labs, clinical trials, and manufacturing, but this information often resides in isolated, non-standardized databases. This fragmentation creates significant hurdles for training robust machine learning models, which depend on comprehensive and integrated datasets. Combining data from different departments or external partners becomes a complex and time-consuming process, limiting the effectiveness of applications such as patient stratification algorithms and real-world evidence analysis. Addressing this requires significant investment in data standardization and integration platforms. A substantial portion of the market, around 21.52%, is in regions actively working to overcome these interoperability challenges.Regulatory and ethical considerations also pose substantial challenges to the widespread implementation of machine learning. The 'black box' nature of some advanced models, particularly in deep learning, conflicts with regulatory demands for transparency and interpretability in drug development. Regulators require clear justification for efficacy and safety claims, and opaque AI models can complicate the approval process. Furthermore, ethical concerns about algorithmic bias and patient privacy are profound. Algorithmic bias, if models are trained on unrepresentative datasets, could lead to health inequities. The absence of globally harmonized regulatory guidelines for AI in pharmaceuticals creates uncertainty, hindering innovation and market entry for new computational biology pipelines and platforms.
Exclusive Customer Landscape
The machine learning in pharmaceutical industry market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the machine learning in pharmaceutical industry market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, machine learning in pharmaceutical industry market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
AbbVie Inc. - The company provides machine learning applications for the pharmaceutical sector, focusing on areas such as AI-driven immunology drug design and target identification for conditions like rheumatoid arthritis. Additionally, it develops specialized data science platforms to support research and development activities within the field of neuroscience.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca Plc
- Atomwise Inc.
- Bayer AG
- Bristol Myers Squibb Co.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- ICON plc
- Insilico Medicine
- IQVIA Holdings Inc.
- Johnson and Johnson Services Inc.
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Recursion Pharmaceuticals Inc.
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Machine Learning In Pharmaceutical Industry Market
In June 2024, Insilico Medicine announced that the first healthy volunteers were dosed in a Phase I clinical trial for ISM5411, a novel PD-1/LAG-3 bispecific antibody for cancer treatment, discovered using its AI platform.In April 2024, AstraZeneca and Flagship Pioneering announced a collaboration to leverage AI and machine learning for novel drug discovery, with Flagship set to receive up to USD 100 million in research funding from AstraZeneca.In March 2024, Pfizer expanded its collaboration with Tempus, a leader in AI and precision medicine, to gain broader access to Tempus's de-identified database and AI-enabled platform to accelerate its oncology drug development programs.In January 2024, Bayer and Google Cloud announced a collaboration to build an AI-powered platform for radiology, aiming to help radiologists reduce time spent on repetitive tasks and focus on higher-value work.
Research Analyst Overview
The global machine learning in pharmaceutical industry market is experiencing a profound transformation, particularly in early-stage development. AI is central to refining the drug discovery design process, using computational chemistry for target identification validation and accelerating the lead optimization process. Advanced models, including generative adversarial networks and variational autoencoders, are enabling de novo drug design and small molecule synthesis. The integration of multi omics data integration, encompassing genomic data analysis and proteomic sequence analysis, enhances ADMET profile prediction and molecular interaction prediction. This evolution extends into clinical phases, where clinical trial optimization is achieved through adaptive clinical trial design, sophisticated patient stratification algorithms, and biomarker identification, with a growing emphasis on digital biomarker integration for more dynamic trial management.Beyond research and development, the operational landscape is adapting through machine learning applications. In manufacturing, the focus is shifting toward predictive maintenance manufacturing and real time quality control, supported by computer vision inspection and process analytical technology to ensure consistency. Concurrently, supply chain logistics are being optimized through demand forecasting analytics. In the post-approval stage, the industry is leveraging real world evidence analysis and pharmacovigilance automation to monitor outcomes, while treatment adherence programs are personalized using AI-driven insights. The adoption of federated learning models allows for collaborative analysis, and regulatory compliance automation is streamlining processes. The sector is widely anticipated to reflect an expansion of over 30% in AI integration for these operational functions.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Machine Learning In Pharmaceutical Industry Market insights. See full methodology.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
323
|
|
Base year
|
2024
|
|
Historic period
|
2019 - 2023 |
|
Forecast period
|
2025-2029
|
|
Growth momentum & CAGR
|
Accelerating at a CAGR of 37.1%
|
|
Market growth 2024-2029
|
USD 10.2 billion
|
|
Market structure
|
Fragmented
|
|
YoY growth 2024-2029(%)
|
34.6%
|
|
Key countries
|
US, Canada, Mexico, China, India, Japan, South Korea, Australia, Indonesia, Germany, UK, France, Italy, The Netherlands, Spain, Brazil, Argentina, Colombia, Saudi Arabia, UAE, South Africa, Israel, Turkey
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
What are the Key Data Covered in this Machine Learning In Pharmaceutical Industry Market Research and Growth Report?
- CAGR of the Machine Learning In Pharmaceutical Industry industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2024 and 2029
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, APAC, Europe, South America, Middle East and Africa
- Thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the machine learning in pharmaceutical industry market growth of industry companies
We can help! Our analysts can customize this machine learning in pharmaceutical industry market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by Technology
- Executive Summary - Chart on Market Segmentation by Deployment
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Chart on Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Chart on Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Chart on Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3 Market Landscape
- 3.1 Market ecosystem
- Chart on Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Chart on Market characteristics analysis
- 3.3 Value chain analysis
- Chart on Value chain analysis
4 Market Sizing
- 4 Market Sizing
- 4.1 Market definition
- Data Table on Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ billion)
- Data Table on Global - Market size and forecast 2024-2029 ($ billion)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5 Historic Market Size
- 5.1 Global Machine Learning In Pharmaceutical Industry Market 2019 - 2023
- Historic Market Size - Data Table on Global Machine Learning In Pharmaceutical Industry Market 2019 - 2023 ($ billion)
- 5.2 Application segment analysis 2019 - 2023
- Historic Market Size - Application Segment 2019 - 2023 ($ billion)
- 5.3 Technology segment analysis 2019 - 2023
- Historic Market Size - Technology Segment 2019 - 2023 ($ billion)
- 5.4 Deployment segment analysis 2019 - 2023
- Historic Market Size - Deployment Segment 2019 - 2023 ($ billion)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ billion)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ billion)
6 Five Forces Analysis
- 6 Five Forces Analysis
- 6.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 6.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 6.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 6.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 6.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 6.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 6.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
7 Market Segmentation by Application
- 7 Market Segmentation by Application
- 7.1 Market segments
- Chart on Application - Market share 2024-2029 (%)
- Data Table on Application - Market share 2024-2029 (%)
- 7.2 Comparison by Application
- Chart on Comparison by Application
- Data Table on Comparison by Application
- 7.3 Drug discovery and design - Market size and forecast 2024-2029
- Chart on Drug discovery and design - Market size and forecast 2024-2029 ($ billion)
- Data Table on Drug discovery and design - Market size and forecast 2024-2029 ($ billion)
- Chart on Drug discovery and design - Year-over-year growth 2024-2029 (%)
- Data Table on Drug discovery and design - Year-over-year growth 2024-2029 (%)
- 7.4 Clinical trial optimization - Market size and forecast 2024-2029
- Chart on Clinical trial optimization - Market size and forecast 2024-2029 ($ billion)
- Data Table on Clinical trial optimization - Market size and forecast 2024-2029 ($ billion)
- Chart on Clinical trial optimization - Year-over-year growth 2024-2029 (%)
- Data Table on Clinical trial optimization - Year-over-year growth 2024-2029 (%)
- 7.5 Disease diagnosis and biomarker identification - Market size and forecast 2024-2029
- Chart on Disease diagnosis and biomarker identification - Market size and forecast 2024-2029 ($ billion)
- Data Table on Disease diagnosis and biomarker identification - Market size and forecast 2024-2029 ($ billion)
- Chart on Disease diagnosis and biomarker identification - Year-over-year growth 2024-2029 (%)
- Data Table on Disease diagnosis and biomarker identification - Year-over-year growth 2024-2029 (%)
- 7.6 Manufacturing and quality control - Market size and forecast 2024-2029
- Chart on Manufacturing and quality control - Market size and forecast 2024-2029 ($ billion)
- Data Table on Manufacturing and quality control - Market size and forecast 2024-2029 ($ billion)
- Chart on Manufacturing and quality control - Year-over-year growth 2024-2029 (%)
- Data Table on Manufacturing and quality control - Year-over-year growth 2024-2029 (%)
- 7.7 Others - Market size and forecast 2024-2029
- Chart on Others - Market size and forecast 2024-2029 ($ billion)
- Data Table on Others - Market size and forecast 2024-2029 ($ billion)
- Chart on Others - Year-over-year growth 2024-2029 (%)
- Data Table on Others - Year-over-year growth 2024-2029 (%)
- 7.8 Market opportunity by Application
- Market opportunity by Application ($ billion)
- Data Table on Market opportunity by Application ($ billion)
8 Market Segmentation by Technology
- 8 Market Segmentation by Technology
- 8.1 Market segments
- Chart on Technology - Market share 2024-2029 (%)
- Data Table on Technology - Market share 2024-2029 (%)
- 8.2 Comparison by Technology
- Chart on Comparison by Technology
- Data Table on Comparison by Technology
- 8.3 Supervised learning - Market size and forecast 2024-2029
- Chart on Supervised learning - Market size and forecast 2024-2029 ($ billion)
- Data Table on Supervised learning - Market size and forecast 2024-2029 ($ billion)
- Chart on Supervised learning - Year-over-year growth 2024-2029 (%)
- Data Table on Supervised learning - Year-over-year growth 2024-2029 (%)
- 8.4 Deep learning - Market size and forecast 2024-2029
- Chart on Deep learning - Market size and forecast 2024-2029 ($ billion)
- Data Table on Deep learning - Market size and forecast 2024-2029 ($ billion)
- Chart on Deep learning - Year-over-year growth 2024-2029 (%)
- Data Table on Deep learning - Year-over-year growth 2024-2029 (%)
- 8.5 Unsupervised learning - Market size and forecast 2024-2029
- Chart on Unsupervised learning - Market size and forecast 2024-2029 ($ billion)
- Data Table on Unsupervised learning - Market size and forecast 2024-2029 ($ billion)
- Chart on Unsupervised learning - Year-over-year growth 2024-2029 (%)
- Data Table on Unsupervised learning - Year-over-year growth 2024-2029 (%)
- 8.6 Reinforcement learning - Market size and forecast 2024-2029
- Chart on Reinforcement learning - Market size and forecast 2024-2029 ($ billion)
- Data Table on Reinforcement learning - Market size and forecast 2024-2029 ($ billion)
- Chart on Reinforcement learning - Year-over-year growth 2024-2029 (%)
- Data Table on Reinforcement learning - Year-over-year growth 2024-2029 (%)
- 8.7 Others - Market size and forecast 2024-2029
- Chart on Others - Market size and forecast 2024-2029 ($ billion)
- Data Table on Others - Market size and forecast 2024-2029 ($ billion)
- Chart on Others - Year-over-year growth 2024-2029 (%)
- Data Table on Others - Year-over-year growth 2024-2029 (%)
- 8.8 Market opportunity by Technology
- Market opportunity by Technology ($ billion)
- Data Table on Market opportunity by Technology ($ billion)
9 Market Segmentation by Deployment
- 9 Market Segmentation by Deployment
- 9.1 Market segments
- Chart on Deployment - Market share 2024-2029 (%)
- Data Table on Deployment - Market share 2024-2029 (%)
- 9.2 Comparison by Deployment
- Chart on Comparison by Deployment
- Data Table on Comparison by Deployment
- 9.3 Cloud-based - Market size and forecast 2024-2029
- Chart on Cloud-based - Market size and forecast 2024-2029 ($ billion)
- Data Table on Cloud-based - Market size and forecast 2024-2029 ($ billion)
- Chart on Cloud-based - Year-over-year growth 2024-2029 (%)
- Data Table on Cloud-based - Year-over-year growth 2024-2029 (%)
- 9.4 Hybrid - Market size and forecast 2024-2029
- Chart on Hybrid - Market size and forecast 2024-2029 ($ billion)
- Data Table on Hybrid - Market size and forecast 2024-2029 ($ billion)
- Chart on Hybrid - Year-over-year growth 2024-2029 (%)
- Data Table on Hybrid - Year-over-year growth 2024-2029 (%)
- 9.5 On premises - Market size and forecast 2024-2029
- Chart on On premises - Market size and forecast 2024-2029 ($ billion)
- Data Table on On premises - Market size and forecast 2024-2029 ($ billion)
- Chart on On premises - Year-over-year growth 2024-2029 (%)
- Data Table on On premises - Year-over-year growth 2024-2029 (%)
- 9.6 Market opportunity by Deployment
- Market opportunity by Deployment ($ billion)
- Data Table on Market opportunity by Deployment ($ billion)
10 Customer Landscape
- 10 Customer Landscape
- 10.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
11 Geographic Landscape
- 11 Geographic Landscape
- 11.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 11.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 11.3 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ billion)
- Data Table on North America - Market size and forecast 2024-2029 ($ billion)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - North America
- Data Table on Regional Comparison - North America
- 11.3.1 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ billion)
- Data Table on US - Market size and forecast 2024-2029 ($ billion)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 11.3.2 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ billion)
- Data Table on Canada - Market size and forecast 2024-2029 ($ billion)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 11.3.3 Mexico - Market size and forecast 2024-2029
- Chart on Mexico - Market size and forecast 2024-2029 ($ billion)
- Data Table on Mexico - Market size and forecast 2024-2029 ($ billion)
- Chart on Mexico - Year-over-year growth 2024-2029 (%)
- Data Table on Mexico - Year-over-year growth 2024-2029 (%)
- 11.4 APAC - Market size and forecast 2024-2029
- Chart on APAC - Market size and forecast 2024-2029 ($ billion)
- Data Table on APAC - Market size and forecast 2024-2029 ($ billion)
- Chart on APAC - Year-over-year growth 2024-2029 (%)
- Data Table on APAC - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - APAC
- Data Table on Regional Comparison - APAC
- 11.4.1 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ billion)
- Data Table on China - Market size and forecast 2024-2029 ($ billion)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 11.4.2 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ billion)
- Data Table on India - Market size and forecast 2024-2029 ($ billion)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
- 11.4.3 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ billion)
- Data Table on Japan - Market size and forecast 2024-2029 ($ billion)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 11.4.4 South Korea - Market size and forecast 2024-2029
- Chart on South Korea - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Korea - Market size and forecast 2024-2029 ($ billion)
- Chart on South Korea - Year-over-year growth 2024-2029 (%)
- Data Table on South Korea - Year-over-year growth 2024-2029 (%)
- 11.4.5 Australia - Market size and forecast 2024-2029
- Chart on Australia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Australia - Market size and forecast 2024-2029 ($ billion)
- Chart on Australia - Year-over-year growth 2024-2029 (%)
- Data Table on Australia - Year-over-year growth 2024-2029 (%)
- 11.4.6 Indonesia - Market size and forecast 2024-2029
- Chart on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Chart on Indonesia - Year-over-year growth 2024-2029 (%)
- Data Table on Indonesia - Year-over-year growth 2024-2029 (%)
- 11.5 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ billion)
- Data Table on Europe - Market size and forecast 2024-2029 ($ billion)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Europe
- Data Table on Regional Comparison - Europe
- 11.5.1 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ billion)
- Data Table on Germany - Market size and forecast 2024-2029 ($ billion)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 11.5.2 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ billion)
- Data Table on UK - Market size and forecast 2024-2029 ($ billion)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 11.5.3 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ billion)
- Data Table on France - Market size and forecast 2024-2029 ($ billion)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 11.5.4 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ billion)
- Data Table on Italy - Market size and forecast 2024-2029 ($ billion)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 11.5.5 The Netherlands - Market size and forecast 2024-2029
- Chart on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Data Table on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Chart on The Netherlands - Year-over-year growth 2024-2029 (%)
- Data Table on The Netherlands - Year-over-year growth 2024-2029 (%)
- 11.5.6 Spain - Market size and forecast 2024-2029
- Chart on Spain - Market size and forecast 2024-2029 ($ billion)
- Data Table on Spain - Market size and forecast 2024-2029 ($ billion)
- Chart on Spain - Year-over-year growth 2024-2029 (%)
- Data Table on Spain - Year-over-year growth 2024-2029 (%)
- 11.6 South America - Market size and forecast 2024-2029
- Chart on South America - Market size and forecast 2024-2029 ($ billion)
- Data Table on South America - Market size and forecast 2024-2029 ($ billion)
- Chart on South America - Year-over-year growth 2024-2029 (%)
- Data Table on South America - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - South America
- Data Table on Regional Comparison - South America
- 11.6.1 Brazil - Market size and forecast 2024-2029
- Chart on Brazil - Market size and forecast 2024-2029 ($ billion)
- Data Table on Brazil - Market size and forecast 2024-2029 ($ billion)
- Chart on Brazil - Year-over-year growth 2024-2029 (%)
- Data Table on Brazil - Year-over-year growth 2024-2029 (%)
- 11.6.2 Argentina - Market size and forecast 2024-2029
- Chart on Argentina - Market size and forecast 2024-2029 ($ billion)
- Data Table on Argentina - Market size and forecast 2024-2029 ($ billion)
- Chart on Argentina - Year-over-year growth 2024-2029 (%)
- Data Table on Argentina - Year-over-year growth 2024-2029 (%)
- 11.6.3 Colombia - Market size and forecast 2024-2029
- Chart on Colombia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Colombia - Market size and forecast 2024-2029 ($ billion)
- Chart on Colombia - Year-over-year growth 2024-2029 (%)
- Data Table on Colombia - Year-over-year growth 2024-2029 (%)
- 11.7 Middle East and Africa - Market size and forecast 2024-2029
- Chart on Middle East and Africa - Market size and forecast 2024-2029 ($ billion)
- Data Table on Middle East and Africa - Market size and forecast 2024-2029 ($ billion)
- Chart on Middle East and Africa - Year-over-year growth 2024-2029 (%)
- Data Table on Middle East and Africa - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Middle East and Africa
- Data Table on Regional Comparison - Middle East and Africa
- 11.7.1 Saudi Arabia - Market size and forecast 2024-2029
- Chart on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Chart on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- Data Table on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- 11.7.2 UAE - Market size and forecast 2024-2029
- Chart on UAE - Market size and forecast 2024-2029 ($ billion)
- Data Table on UAE - Market size and forecast 2024-2029 ($ billion)
- Chart on UAE - Year-over-year growth 2024-2029 (%)
- Data Table on UAE - Year-over-year growth 2024-2029 (%)
- 11.7.3 South Africa - Market size and forecast 2024-2029
- Chart on South Africa - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Africa - Market size and forecast 2024-2029 ($ billion)
- Chart on South Africa - Year-over-year growth 2024-2029 (%)
- Data Table on South Africa - Year-over-year growth 2024-2029 (%)
- 11.7.4 Israel - Market size and forecast 2024-2029
- Chart on Israel - Market size and forecast 2024-2029 ($ billion)
- Data Table on Israel - Market size and forecast 2024-2029 ($ billion)
- Chart on Israel - Year-over-year growth 2024-2029 (%)
- Data Table on Israel - Year-over-year growth 2024-2029 (%)
- 11.7.5 Turkey - Market size and forecast 2024-2029
- Chart on Turkey - Market size and forecast 2024-2029 ($ billion)
- Data Table on Turkey - Market size and forecast 2024-2029 ($ billion)
- Chart on Turkey - Year-over-year growth 2024-2029 (%)
- Data Table on Turkey - Year-over-year growth 2024-2029 (%)
- 11.8 Market opportunity by geography
- Market opportunity by geography ($ billion)
- Data Tables on Market opportunity by geography ($ billion)
12 Drivers, Challenges, and Opportunity
- 12 Drivers, Challenges, and Opportunity
- 12.1 Market drivers
- Increasing data volume and complexity
- Quest for enhanced efficiency and reduced costs
- Personalized medicine and precision therapies
- 12.2 Market challenges
- Data silos and interoperability issues
- Regulatory and ethical considerations
- Talent gap and skill shortages
- 12.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 12.4 Market opportunities
- Rise of generative AI for de novo drug design
- Increasing adoption of federated learning for data privacy
- Integration of AI with digital biomarkers and wearable technology
13 Competitive Landscape
- 13 Competitive Landscape
- 13.1 Overview
- 13.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 13.3 Landscape disruption
- Overview on factors of disruption
- 13.4 Industry risks
- Impact of key risks on business
14 Competitive Analysis
- 14 Competitive Analysis
- 14.1 Companies profiled
- 14.2 Company ranking index
- 14.3 Market positioning of companies
- Matrix on companies position and classification
- 14.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Product / Service
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- SWOT
- 14.5 Amgen Inc.
- Amgen Inc. - Overview
- Amgen Inc. - Product / Service
- Amgen Inc. - Key news
- Amgen Inc. - Key offerings
- SWOT
- 14.6 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Product / Service
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- SWOT
- 14.7 Bayer AG
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key news
- Bayer AG - Key offerings
- Bayer AG - Segment focus
- SWOT
- 14.8 Bristol Myers Squibb Co.
- Bristol Myers Squibb Co. - Overview
- Bristol Myers Squibb Co. - Product / Service
- Bristol Myers Squibb Co. - Key news
- Bristol Myers Squibb Co. - Key offerings
- SWOT
- 14.9 Eli Lilly and Co.
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Product / Service
- Eli Lilly and Co. - Key offerings
- SWOT
- 14.10 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 14.11 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- 14.12 IQVIA Holdings Inc.
- IQVIA Holdings Inc. - Overview
- IQVIA Holdings Inc. - Business segments
- IQVIA Holdings Inc. - Key offerings
- IQVIA Holdings Inc. - Segment focus
- SWOT
- 14.13 Johnson and Johnson Services Inc.
- Johnson and Johnson Services Inc. - Overview
- Johnson and Johnson Services Inc. - Business segments
- Johnson and Johnson Services Inc. - Key news
- Johnson and Johnson Services Inc. - Key offerings
- Johnson and Johnson Services Inc. - Segment focus
- SWOT
- 14.14 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 14.15 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 14.16 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Product / Service
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- SWOT
- 14.17 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 14.18 Takeda Pharmaceutical Co. Ltd.
- Takeda Pharmaceutical Co. Ltd. - Overview
- Takeda Pharmaceutical Co. Ltd. - Product / Service
- Takeda Pharmaceutical Co. Ltd. - Key news
- Takeda Pharmaceutical Co. Ltd. - Key offerings
- SWOT
15 Appendix
- 15 Appendix
- 15.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 15.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 15.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 15.4 Research methodology
- 15.5 Data procurement
- 15.6 Data validation
- 15.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 15.8 Data synthesis
- 15.9 360 degree market analysis
- 360 degree market analysis
- 15.10 List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
